Impact of MEK inhibitor therapy on neurocognition in neurofibromatosis type 1

Karin S. Walsh, Pamela L. Wolters, Brigitte C. Widemann, Allison A. del Castillo, Maegan D. Sady, Tess Inker, Marie Claire Roderick, Staci Martin, Mary Anne Toledo-Tamula, Kari Struemph, Iris Paltin, Victoria Collier, Kathy Mullin, Michael J. Fisher, Roger J. Packer
doi: https://doi.org/10.1101/2020.12.18.20248334

Article usage

Article usage: December 2020 to August 2025

AbstractFullPdf
Dec 2020258048
Jan 2021100238
Feb 202185412
Mar 2021732524
Apr 202188321
May 2021561318
Jun 202159812
Jul 2021381438
Aug 2021321831
Sep 202127828
Oct 202118130
Nov 202128621
Dec 20211274
Jan 202219818
Feb 20221808
Mar 2022863
Apr 202225920
May 202218411
Jun 20222605
Jul 20221400
Aug 20221765
Sep 20222728
Oct 20222518
Nov 20221524
Dec 20221236
Jan 20231212
Feb 2023996
Mar 20231285
Apr 20232052
May 2023838
Jun 2023951
Jul 2023424
Aug 202315156
Sep 20231142
Oct 2023541
Nov 202315103
Dec 2023602
Jan 2024952
Feb 20241241
Mar 2024747
Apr 202418179
May 2024462
Jun 20241422
Jul 2024562
Aug 2024825
Sep 20241877
Oct 2024652
Nov 20241487
Dec 20248613
Jan 202517513
Feb 2025103310
Mar 2025223113
Apr 2025131414
May 2025112014
Jun 202522817
Jul 2025241425
Aug 2025214
Back to top
Posted December 20, 2020.
Download PDF
Data/Code
Email
Impact of MEK inhibitor therapy on neurocognition in neurofibromatosis type 1
Karin S. Walsh, Pamela L. Wolters, Brigitte C. Widemann, Allison A. del Castillo, Maegan D. Sady, Tess Inker, Marie Claire Roderick, Staci Martin, Mary Anne Toledo-Tamula, Kari Struemph, Iris Paltin, Victoria Collier, Kathy Mullin, Michael J. Fisher, Roger J. Packer
medRxiv 2020.12.18.20248334; doi: https://doi.org/10.1101/2020.12.18.20248334
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area